# PRODUCT INFORMATION

## ADB-BUTINACA-$d_9$

*Item No. 38341*

| | |
|---|---|
| **Formal Name:** | N-[(1S)-1-(aminocarbonyl)-2,2-dimethylpropyl]-1-butyl-$d_9$-1H-indazole-3-carboxamide |
| **MF:** | $C_{18}H_{17}D_9N_4O_2$ |
| **FW:** | 339.5 |
| **Chemical Purity:** | ≥98% (ADB-BUTINACA) |
| **Deuterium Incorporation:** | ≥99% deuterated forms ($d_1$-$d_9$); ≤1% $d_0$ |
| **UV/Vis.:** | $\lambda_{max}$: 210, 303 nm |
| **Supplied as:** | A crystalline solid |
| **Storage:** | -20°C |
| **Stability:** | ≥2 years |



*Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.*

## Description

ADB-BUTINACA-$d_9$ (Item No. 38341) is intended for use as an internal standard for the quantification of ADB-BUTINACA (Item No. 29350) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

ADB-BUTINACA is categorized as a synthetic cannabinoid.[1] ADB-BUTINACA-$d_9$ is regulated as a Schedule I compound in the United States. This product is intended for research and forensic applications.

## Reference


1. Sparkes, E., Cairns, E.A., Kevin, R.C., *et al.* Structure-activity relationships of valine, *tert*-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. *RSC Med. Chem.* **13(2)**, 156-174 (2021).





**CAYMAN CHEMICAL**
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
**PHONE:** [800] 364-9897
[734] 971-3335
**FAX:** [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM